| scholarly article | Q13442814 |
| P50 | author | George D Demetri | Q96229532 |
| Jerry Younger | Q125264020 | ||
| Eric Winer | Q16887072 | ||
| Larry Norton | Q37644083 | ||
| Cancer and Leukemia Group B | Q62569336 | ||
| Gloria Broadwater | Q87013225 | ||
| Nancy U Lin | Q89531596 | ||
| Minetta C Liu | Q89668739 | ||
| Clifford A Hudis | Q92892082 | ||
| P2093 | author name string | David Duggan | |
| Donald A Berry | |||
| Nicholas J Robert | |||
| Daniel F Hayes | |||
| P Kelly Marcom | |||
| Peter A Kaufman | |||
| I Craig Henderson | |||
| Katherine Tkaczuk | |||
| Judith Hopkins | |||
| Alan Lyss | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group | Q33328841 | ||
| Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer | Q33371932 | ||
| Dose-response in the treatment of breast cancer: a critical review | Q39522432 | ||
| The importance of dose intensity in chemotherapy of metastatic breast cancer | Q40190080 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer | Q46658468 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results | Q68536818 | ||
| Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience | Q69918671 | ||
| Preliminary experience with paclitaxel (Taxol) plus recombinant human granulocyte colony-stimulating factor in the treatment of breast cancer | Q72089503 | ||
| Dose: a critical factor in cancer chemotherapy | Q72154949 | ||
| Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma | Q72174351 | ||
| Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25 | Q73153238 | ||
| Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22 | Q73368640 | ||
| Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B | Q77156165 | ||
| Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group | Q77347398 | ||
| P433 | issue | 3 | |
| P921 | main subject | doxorubicin | Q18936 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 223-230 | |
| P577 | publication date | 2008-01-30 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide follow | |
| P478 | volume | 34 |
| Q34233936 | Dose-dense epirubicin and cyclophosphamide followed by weekly Paclitaxel in node-positive breast cancer |
| Q37576235 | Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials |
| Q34620664 | Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications |
| Q39649049 | Immunity to Trop-1, a newly identified breast cancer antigen, inhibits the growth of breast cancer in mice |
| Q33928011 | Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy |
| Q89950670 | Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome |
| Q35026985 | Uptake of novel medical therapies in the general population |
Search more.